Infectious Disease Clinics of North America volume 24, issue 3, P681-692 2010 DOI: 10.1016/j.idc.2010.04.010 View full text
|
|
Share
Robert S. Wallis, Neil W. Schluger

Abstract: The understanding of the infection risks posed by tumor necrosis factor (TNF) antagonists has continued to evolve in the 10 years since these drugs first were introduced. Recent prospective studies have confirmed the risk of tuberculosis (TB) reactivation posed by TNF antibodies to be several fold greater than soluble TNF receptor. Certolizumab pegol, a monovalent anti-TNF Fab' fragment, appears to share this risk, despite its lack of Fc and its inability to cross-link transmembrane TNF or activate complement.…

expand abstract